Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma by unknown
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Shimizu et al. World Journal of Surgical Oncology 2014, 12:343
http://www.wjso.com/content/12/1/343RESEARCH Open AccessDifference in prognostic values of maximal
standardized uptake value on fluorodeoxyglucose-
positron emission tomography and
cyclooxygenase-2 expression between lung
adenocarcinoma and squamous cell carcinoma
Katsuhiko Shimizu*, Ai Maeda, Takuro Yukawa, Yuji Nojima, Shinsuke Saisho, Riki Okita and Masao NakataAbstract
Background: The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography
(FDG-PET) for primary tumors is correlated with clinicopathological and prognostic factors in patients with non-small
cell lung cancer. However, previous investigations have discussed the role of SUVmax without distinguishing among
the histological subtypes of lung cancer. Herein, we investigated the correlations among the SUVmax on FDG-PET,
clinicopathological or prognostic factors, and the expression of tumor angiogenic biomarkers according to
histological subtypes.
Methods: We conducted a retrospective review of data from 52 patients with invasive adenocarcinoma (ADC)
and 32 patients with squamous cell carcinoma (SQC) measuring less than 3 cm in diameter.
Immunohistochemical staining for cyclooxygenase-2 (Cox-2), Ki-67, and vascular endothelial growth factor,
which might influence cancer progression, was performed and the correlations between the expressions of
these biomarkers and the SUVmax were evaluated.
Results: Among ADC patients, a statistically significant correlation was observed between the SUVmax and the
major clinicopathological factors; among SQC patients, however, no statistically significant association was
observed. The disease-free survival (DFS) period of the ADC patients with a high SUVmax was significantly
poorer than that of the patients with a low SUVmax, but the DFS of the SQC patients with a high SUVmax was
not significantly poorer. In a multivariate analysis, the pathological stage and the SUVmax were independent
prognostic factors of the DFS among the ADC patients. Among the SQC patients, however, only Cox-2 expression was
an independent prognostic factor of DFS.
Conclusions: Some clear differences in prognostic values of the SUVmax on FDG-PET and Cox-2 expression exist between
patients with ADC and those with SQC. Based on these relationships between the SUVmax and clinicopathological or
biological factors that influence cancer progression, the importance of the SUVmax appears to be quite different
for patients with ADC and those with SQC.
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Table 1 Patient characteristics
Factor All cases ADC SQC P value
Number 84 52 32
Age (Mean ± SD) 66.7 ± 8.6 72.7 ± 7.8 0.002
Sex <0.001
Male 56 24 32
Female 28 28 0
Tumor size (Mean ± SD) 22.4 ± 6.9 21.2 ± 6.9 0.423
Pathological stage (%) 0.595
IA 55 36(69) 19(60)
IB 14 8(15) 6(19)
IIA + B 6 3(6) 3(9)
IIIA + B 9 5(10) 4(12)
SUVmax (Mean ± SD) 7.4 ± 4.7 6.6 ± 5.2 8.8 ± 3.7 0.032
ADC: adenocarcinoma, SQC: squamous cell carcinoma.
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Fluorodeoxyglucose-positron emission tomography (FDG-
PET) has become an important tool for the diagnosis and
staging of non-small cell lung cancer (NSCLC) [1]. The
maximal standardized uptake value (SUVmax) on FDG-
PET is the ratio of the activity in the tissue per unit vol-
ume relative to the injected dose according to body
weight, and this parameter is widely used because of its
simplicity. The SUVmax of primary tumors has been
shown to be correlated with the stage, nodal status, histo-
logical type, differentiation, and progression of tumors in
patients with NSCLC [2-4]. In addition, a high SUVmax
has been reported to be a powerful prognostic factor in
patients with NSCLC [4-6].
Recently, several studies have reported the existence of a
relationship between FDG uptake and the expressions of
some molecular biomarkers. Of these, the most famous
biomarker related to the SUVmax is glucose transporter 1
[7]. Several other studies have investigated the correlation
between FDG uptake and the expressions of biological
markers of lung cancer, such as Ki-67, p53, and vascular
endothelial growth factor (VEGF) [8-10]. In 2012, we
demonstrated that the expression of cyclooxygenase-2
(Cox-2) in tumors was as strongly correlated with a poor
clinical outcome as an increase in FDG uptake in lung
adenocarcinoma [11].
However, these investigations discussed the role of SUV-
max without distinguishing among histological subtypes
of lung cancer. Therefore, we investigated the correlation
among the expression of selective tumor biomarkers, the
SUVmax on FDG-PET, and clinicopathological or prog-
nostic factors according to histological subtypes, specific-




A total of 52 patients with invasive ADC and 32 patients
with SQC measuring less than 3 cm in diameter, who
had undergone surgical resection with systematic lymph
node dissection at Kawasaki Medical School Hospital be-
tween 2007 and 2010, were enrolled in this study. We
restricted the tumor size to less than 3 cm in diameter
because the SUVmax is known to be higher in large tu-
mors [4,12]. Furthermore, ADC was limited to radiologic
‘invasive’ ADC. Invasive ADC was defined based on the
radiologic criteria of a consolidation-to-tumor ratio of
greater than 0.50 [13]. None of the patients had received
either radiotherapy or chemotherapy prior to the sur-
gery. The histological diagnosis of the tumors was based
on the criteria of the World Health Organization, and
the TNM stage was determined according to the cri-
teria established in 2009. Written informed consent
was obtained from each patient for the study of theexcised tissue samples from the surgical specimens.
This study was conducted with the approval of the insti-
tutional ethics committee of Kawasaki Medical School.
(number: 1396, approved on 13 May 13 2013).
Fluorodeoxyglucose-positron emission tomography
In our institute, all patients with lung cancer had under-
gone FDG-PET before surgery. However, patients with
blood glucose levels of 150 mg/dL or more were ex-
cluded from positron emission tomography/computed
tomography (PET/CT) acquisition. All PET/CT exami-
nations were performed using a dedicated PET/CT scan-
ner (Discovery ST Elite; GE Healthcare, Tokyo, Japan).
PET/CT scanning was performed at 60 minutes after the
intravenous injection of 150 to 220 MBq of 18FDG
(FDGscan, Universal Giken, Nihon Mediphysics, Tokyo,
Japan). The regions of interest (ROI) were placed three-
dimensionally over the lung cancer nodules. A semi-
quantitative analysis of the images was performed by
measuring the SUVmax of the lesions. The SUV was cal-
culated based on the following equation:
Tumor activity concentration= Injected dose=Body weightð Þ
Immunohistochemical staining
Immunohistochemical analyses of resected, paraffin-
embedded lung cancer tissues were performed. After
microtome sectioning (4 μm thickness), the slides were
processed for staining using an automated immunos-
tainer (Nexes; Ventana, Tucson, Arizona, United States).
The streptavidin-biotin-peroxidase detection technique,
using 3,3'-diaminobenzidine as the chromogen, was ap-
plied. The primary antibodies were used according to the
manufacturer’s instructions (Cox-2: DakoCytomation,
CX-294, CA, USA, 1/50 dilution; Ki-67: DakoCytomation,
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sc-152, CA, USA, 1:300 dilution). The slides were ex-
amined by two investigators who had no knowledge of
the clinicopathological data. The expression of each
marker protein was examined and evaluated according
to a previously reported original protocol. For Cox-2,
the slides were scored for the intensity of staining (0 to 3)
and the percentages of cells with scores of zero (0%), one
(1 to 9%), two (10 to 49%), and three (50 to 100%) were
determined. The immunohistochemistry (IHC) score (zero
to nine) was defined as the product of the intensity and
percentage of the cells. Cox-2 expression was judged as
positive when the IHC score was four or more [14]. The
labeling index of Ki-67 was measured by determining the
percentage of cells with positively stained nuclei. Ki-67Table 2 Relationship between the SUVmax and clinicopatholo
ADC SUVmax
Factor (n =52) (Mean ± SD)
Age
<70 years 30 6.4 ± 5.1
≥70 years 22 6.9 ± 5.3
Sex
Male 24 7.6 ± 5.5
Female 28 5.8 ± 4.8
Tumor differentiation
Well 30 4.1 ± 3.3
Moderate 16 8.5 ± 5.4
Poor 6 14.1 ± 2.7
Pleural invasion
No 38 5.0 ± 4.0
Yes 14 11.1 ± 5.4
Vascular invasion
No 33 4.7 ± 4.0
Yes 19 9.9 ± 5.5
Nodal status
Negative 44 5.6 ± 4.6
Positive 8 12.0 ± 4.9
Cox-2 expression
Negative 18 2.8 ± 2.4
Positive 34 8.7 ± 5.1
Ki-67 expression
Negative 26 4.3 ± 3.3
Positive 26 9.0 ± 5.7
VEGF expression
Negative 17 3.9 ± 4.1
Positive 35 8.0 ± 5.1
ADC: adenocarcinoma, Cox-2, cyclooxygenase-2; IHC, immunohistochemical; SQC: sq
vascular endothelial growth factor.expression was judged as positive when more than 10% of
the cancer cell nuclei showed positive staining [15]. VEGF
expression was judged as positive when more than 20% of
the cancer cell cytoplasm showed positive staining [16].
Statistical analysis
All the statistical analyses were performed using the
SPSS statistical package (version 17.0; SPSS, Chicago,
Illinois, United States). Frequencies were compared using
the chi-square test for categorical variables, and the Fischer
exact test was applied for small samples. Mann-Whitney U
tests were performed when comparing continuous vari-
ables. Receiver operating characteristic (ROC) curves of
the SUVmax for the prediction of recurrence were gener-
ated to determine the cutoff value that yielded an optimalgical/IHC findings
SQC SUVmax
P value (n =32) (Mean ± SD) P value
0.778 0.747
11 8.4 ± 4.5
21 8.9 ± 3.4
0.230 -
32 8.8 ± 3.7
0
0.008 0.565
2 12.0 ± 2.1
21 8.3 ± 3.9
9 9.1 ± 3.6
0.001 0.077
26 8.2 ± 3.7
6 11.2 ± 3.2
0.001 0.602
18 9.1 ± 3.8
14 8.4 ± 3.7
0.007 0.075
26 8.1 ± 3.5
6 11.6 ± 3.7
<0.001 0.048
19 7.7 ± 3.6
13 10.3 ± 3.5
0.001 0.016
15 7.0 ± 4.0
17 10.3 ± 2.9
0.004 0.719
16 9.0 ± 4.3
16 8.5 ± 3.3
uamous cell carcinoma; SUVmax, maximal standardized uptake value; VEGF,
Figure 1 Receiver-operating characteristics (ROC) curve for predicting recurrence. (A) Adenocarcinoma: AUC 0.80 (95% CI: 0.69 to 0.92), P
<0.001. (B) Squamous cell carcinoma: AUC 0.65 (95% CI: 0.38 to 0.92), P =0.257. AUC, area under the curve; CI, confidence interval.
Table 3 Comparison of SUVmax between ADC and SQC
ADC: SUVmax SQC: SUVmax
Factor Low High P value Low High P value
Pleural invasion 0.027 0.064
No 19 19 17 9
Yes 2 12 1 5
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performed by considering the disease-free survival (DFS)
period. DFS was defined as the time until lung cancer
recurrence, second cancer occurrence, or non-lung-
cancer-related death. The DFS was analyzed using the
Kaplan-Meier method. Differences in DFS were assessed
using the log-rank test. To assess the potential independ-
ent effects on the DFS, we performed multivariate ana-
lyses using the Cox proportional hazards model. A P value
of <0.05 was considered as statistically significant.Vascular invasion 0.042 0.735
No 17 16 9 6
Yes 4 15 9 8
Nodal status 0.016 0.365
N0 21 23 16 10
N1 + 2 0 8 2 4
Cox-2 expression 0.001 0.473
Negative 13 5 12 7
Positive 8 26 6 7
Ki-67 expression 0.011 0.087Results
Clinical characteristics
The characteristics of the patients are summarized in
Table 1. A total of 52 patients had invasive ADC, and 32
had SQC. The patients ranged in age from 46 to 83 years
(mean: 69.0 years). There were 56 men and 28 women.
The median value of the SUVmax of all the tumors was
7.4 ± 4.7 (range: 0 to 18.1). The patient age, sex, and
mean SUVmax differed significantly between the histo-
logical subtypes.Negative 15 11 11 4
Positive 6 20 7 10
VEGF expression 0.003 0.999
Negative 12 5 9 7
Positive 9 26 9 7
ADC: adenocarcinoma, Low/High = SUVmax 3.95. SQC: squamous cell
carcinoma, Low/High = SUVmax 9.70. Cox-2, cyclooxygenase-2; SUVmax,
maximal standardized uptake value; VEGF, vascular endothelial growth factor.Relationship between the maximal standardized uptake
value and clinicopathological findings
Among the ADC patients, a statistically significant correl-
ation was observed between the SUVmax and the degree of
tumor differentiation (P =0.008), pleural invasion (P =0.001),
vascular invasion (P =0.001), and nodal status (P =0.007). In
contrast, among the SQC patients, no statistically significant
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of the clinicopathological factors (Table 2).
Relationship between the maximal standardized uptake
value and immunohistochemical findings
Among the ADC patients, the Cox-2-positive, Ki-67-
positive, and VEGF-positive cases showed a significantly
higher SUVmax than the cases that were negative for
these markers. On the other hand, among the SQCFigure 2 Kaplan-Meier disease-free survival curve according to the m
log-rank P <0.001. (B) Squamous cell carcinoma: log-rank P =0.284.patients, the Cox-2-positive and Ki-67-positive cases
showed a significantly higher SUVmax than the cases
that were negative for these markers (Table 2). Using a
multiple stepwise regression analysis, Cox-2 expression
(P =0.007) and Ki-67 expression (P =0.028) remained
as significant factors that were independently related
to the SUVmax in the ADC patients, but only Ki-67
expression (P =0.037) remained significant in the SQC
patients.aximal standardized uptake value (SUVmax). (A) Adenocarcinoma:
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and immunohistochemical findings
We used an ROC curve analysis to evaluate whether the
SUVmax could predict recurrence (Figure 1). The ROC
curves identified an optimal SUVmax cutoff value of
3.95 for predicting recurrence in patients with ADC
(area under the curve (AUC) =0.80, P <0.001), but not
for patients with SQC (AUC =0.65, P =0.257). We di-
vided the patient population based on a SUVmax cutoff
value of 3.95 for the ADC patients and 9.70 for the SQC
patients. Among ADC patients, a high SUVmax was sig-
nificantly correlated with pleural invasion (P =0.027),
vascular invasion (P =0.042), nodal status (P =0.016),
Cox-2 expression (P =0.001), Ki-67 expression (P =0.011),
and VEGF expression (P =0.003) (Table 3). On the other
hand, among the SQC patients, a high SUVmax was not
significantly correlated with these factors.
The DFS of ADC patients with a high SUVmax was
significantly poorer than that of patients with a low
SUVmax (P <0.001, log-rank test; Figure 2A). In con-
trast, the DFS of SQC patients with a high SUVmax was
not significantly poorer than that of patients with a low
SUVmax (P =0.284, log-rank test; Figure 2B). A univari-
ate analysis of DFS was performed using the variables of
pathological stage, SUVmax, Cox-2 expression, Ki-67 ex-
pression, and VEGF expression. Among the ADC pa-
tients, all the variables were associated with DFS; among
the SQC patients, however, only Cox-2 expression was
associated with DFS (Table 4). In a multivariate analysis,
pathological stage and SUVmax were independent prog-
nostic factors for DFS among the ADC patients, but onlyTable 4 Results of the univariate and multivariate cox
regression analysis of disease-free survival
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
A) Adenocarcinoma
Pathological stage 1.26 1.14-1.10 0.001 1.15 1.02-1.30 0.019
SUVmax 19.42 2.58-146.0 0.001 9.19 1.10-76.54 0.040
Cox-2 expression 4.08 1.18-14.04 0.026 1.57 0.40-6.22 0.521
Ki-67 expression 4.44 1.59-12.38 0.004 1.77 0.54-5.77 0.342
VEGF expression 5.52 1.27-23.94 0.023 1.67 0.36-7.78 0.515
B) Squamous cell carcinoma
Pathological stage 1.16 0.99-1.36 0.073 1.09 0.88-1.36 0.432
SUVmax 2.46 0.45-13.43 0.300 1.14 0.14-9.40 0.906
Cox-2 expression 9.46 1.10-81.40 0.041 7.36 1.04-72.05 0.048
Ki-67 expression 1.68 0.31-9.20 0.548 1.32 0.23-7.54 0.753
VEGF expression 0.52 0.10-2.84 0.450 0.62 0.89-4.31 0.627
Pathological stage: I versus II + III. CI, confidence interval; Cox-2,
cyclooxygenase-2; HR, hazard ratio; SUVmax, maximal standardized uptake
value; VEGF, vascular endothelial growth factor.Cox-2 expression was an independent prognostic factor
for DFS among the SQC patients (Table 4).
Discussion
In this study, we investigated the correlations among the
expressions of tumor angiogenic biomarkers, the SUV-
max on FDG-PET, and the prognosis according to histo-
logical subtypes. As a result, some clear differences in
the prognostic value of SUVmax and Cox-2 expression
were observed between ADC and SQC. Until now, most
publications discussing the correlation between the SUV-
max and clinicopathological or prognostic factors have
not investigated tumors according to histological subtype.
Recently, Tsutani et al. reported that the SUVmax of the
primary tumor was a powerful prognostic determinant for
patients with ADC, but not for those with SQC [17]. The
present study provides the evidence showing correlations
among the expressions of biomarkers, the SUVmax, and
prognosis according to histological subtype. The import-
ant findings of this present study were as follows: (i) the
SUVmax was correlated with clinicopathological and bio-
logical factors in patients with ADC, but not in those with
SQC; ii) the SUVmax was a powerful prognostic factor
in patients with ADC, but not in those with SQC; (iii)
Cox-2 expression was a powerful prognostic factor in
patients with SQC, but not in those with ADC. These
findings suggest that the SUVmax had no significant
value when considering therapeutic strategies for pa-
tients with SQC.
The SUVmax of primary lung nodules has been re-
ported to be helpful in distinguishing between malignant
and benign tumors, based on the relatively higher values
that are seen for malignant tumors [18]. We speculated
that tumors showing a higher SUVmax might be more
aggressive and might have a higher proliferation poten-
tial. We then examined this hypothesis by studying the
correlation between the SUVmax and the expressions of
some molecular biomarkers, since the overexpression of
these markers is known to accelerate tumor progression
in NSCLC patients.
Cox-2 expression is highly correlated with tumor angio-
genesis and also regulates other angiogenic factors. Some
investigators have demonstrated that Cox-2 is constitu-
tively overexpressed in a variety of epithelial malignancies,
such as lung, breast, pancreas, colon, esophagus, and head
and neck cancers, and Cox-2 overexpression is usually as-
sociated with a poor prognosis [19,20]. To date, some arti-
cles have investigated the association between Cox-2
expression and tumor angiogenesis [21]. Recent evidence
suggests that Cox-2 plays an important role in tumor-
induced angiogenesis through the synthesis of angiogenic
prostaglandins, which induce VEGF, and that Cox-2
contributes to neovascularization and may support the
vasculature-dependent growth of solid tumors [19].
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SUVmax of primary tumors might reflect the bio-
logical malignant potential, such as tumor angiogen-
esis. Cancer treatment targeting the control of Cox-2
might become feasible in the future. In 2008, Edelman
et al. [14] reported that patients with advanced NSCLC
tumors with moderate to high Cox-2 expression had a
poorer survival outcome than those with a low expres-
sion level. Moreover, patients with moderate to high
Cox-2 expression had a better tumor response to a
Cox-2 inhibitor (celecoxib) in terms of a longer me-
dian survival compared with those not receiving cele-
coxib [14]. On the other hand, in the NVALT-4 study
performed in 2011, celecoxib did not improve survival,
and Cox-2 expression was not a prognostic biomarker
and had no predictive value when celecoxib was added
to chemotherapy. However, in a subset analysis, patients
with SQC seemed to perform better when treated with
celecoxib [22]. Since our results indicate that Cox-2 ex-
pression is an independent prognostic factor in SQC, the
administration of a Cox-2 inhibitor to patients with SQC
seem reasonable.
Immunostaining with the Ki-67 antibody is a widely
accepted method for evaluating proliferative activity in a
variety of human tumors. Vesselle et al. reported the ex-
istence of a relationship between the Ki-67 expression
index and the degree of FDG uptake in NSCLCs [23].
Also in this study, the expression of Ki-67 was signifi-
cantly related to the SUVmax in both ADC and SQC.
On the other hand, the VEGF family of proteins modu-
lates angiogenesis, which is essential for tumor growth
and metastasis. The expression of VEGF has been shown
to be associated with tumor angiogenesis, metastasis,
and prognosis in several cancers, including NSCLC. To
date, two reports have shown a correlation between the
expression of VEGF and the SUV on PET-CT [10,16].
Kaira et al. demonstrated a significant correlation be-
tween VEGF expression and FDG uptake in NSCLCs
[10]. However, our results were not similar to the results
of previous report.
A feature of this study was the histological classifica-
tion of the tumors into ADC and SQC. Recently, clear
evidence has suggested that the classification of NSCLC
into pathologic subtypes is important for the selection of
an appropriate systemic therapy, from the viewpoint of
both treatment efficacy and the prevention of toxicity.
Pemetrexed yields a much better treatment outcome in
patients with ADC than in those with SQC [24]. The use
of bevacizumab has been shown to be associated with an
increased risk of fatal pulmonary hemorrhage in pa-
tients with SQC [25]. Epidermal growth factor receptor
mutations is more commonly encountered in ADC
[26]. Because of the choice of treatment for SQC, fur-
ther studies are needed. The present study suggeststhat a Cox-2 inhibitor might be indicated for the treat-
ment of SQC.
Conclusions
In conclusion, some clear differences were observed in
the prognostic value of Cox-2 expression and the SUV-
max on FDG-PET between patients with ADC and those
with SQC. Among patients with SQC, Cox-2 expression
was a powerful prognostic factor. In patients with ADC,
on the other hand, the SUVmax was a potential bio-
marker of clinical outcome. These findings indicated
that the SUVmax of primary tumors might reflect the
biological malignant potential in ADC, but the SUVmax
had no significant value for determining the therapeutic
strategy in patients with SQC. Further study is needed
to investigate other factors that might influence the
SUVmax on FDG-PET. The small number of patients
was a major limitation of the present study.
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